AI Drug Discovery
Page 1 • 5 itemsUnlock AI drug discovery insights. Track global pharma market trends, investment opportunities, and regulatory impacts for your BD strategy.
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
XtalPi and PharmaEngine's AI-discovered PRMT5 inhibitor PEP08 starts Phase I solid tumor trial, marking major milestone in synthetic lethality cancer treatment.
Insilico Medicine's Rentosertib Inhalation Solution Receives IND Clearance for First AI-Driven Direct-to-Lung Clinical Trial
Insilico Medicine's AI-discovered Rentosertib inhalation solution gets IND clearance for direct-to-lung delivery, marking a milestone in AI drug development.
Sanyou AI-STAL 2.0 Reduces Antibody Discovery Time from Months to 14 Days in Drug Development Breakthrough
Sanyou's AI-STAL 2.0 platform revolutionizes drug discovery by reducing antibody development timelines from months to just 14 days, transforming pharmaceutical R&D.
Gene Expression Analysis Market Reaches $5.93 Billion by 2031, Driving Drug Discovery Innovation
Gene expression analysis market projected to grow from $4.23B in 2026 to $5.93B by 2031 at 7.0% CAGR, led by drug discovery applications.
AI Accelerating NMPA Approvals: What You Need to Know
Explore how artificial intelligence is transforming the NMPA approval process, enhancing the speed and efficiency of drug approvals like XYZ for cancer.